$DLX

DELUXE CORP (DLX): Results of Operations and Financial Condition

DELUXE CORP (DLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991080520268-k.htm EX-99.1 Document Exhibit 99.1 Contact: Brian Anderson, VP, Strategy & Investor Relations Keith Negrin, VP, Communications 651-447-4197 612-669-1459 brian.anderson@deluxe.com keith.negrin@deluxe.com DELUXE REPORTS STRONG SECOND QUARTER 2026 RESU

Original reporting
Published Aug 5, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$DLX
Bullish
medium confidence
Mentioned
$DLX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DLXBullishMed
01

Why it matters

The key tradable items are the raised 2026 revenue, adjusted EBITDA, adjusted diluted EPS, and free cash flow ranges, plus the dividend declaration and credit facility maturity extension to 2031.

02

Market read

This is a guidance update with concrete financial ranges and cash flow metrics, making it relevant for positioning ahead of the earnings call.

03

What to watch

Free cash flow strength is highlighted, but traders may focus on whether the updated ranges assume favorable macro conditions and whether the portfolio exit impacts revenue sustainability beyond the near term.

Relevance 7/10Novelty 8/10Timing: after-hours filing and before the 5:00 p.m. ET earnings call

Background

Deluxe filed an 8-K with Exhibit 99.1 covering Q2 2026 results and updated full-year 2026 guidance after Celero closed on July 31.

Company-level read

Ticker impact

$DLXBullishMedium confidence
Context

Deluxe reported Q2 results and raised full-year 2026 revenue and adjusted EBITDA guidance to incorporate the Celero acquisition.

Expected impact

Moderately positive bias for the next session and into the earnings call, with volatility around how investors underwrite Celero synergies and margin durability.

Evidence & confidence

The filing discloses specific updated 2026 ranges, cash flow/free cash flow improvements, and credit-facility maturity extension, all of which are actionable for valuation and positioning. However, GAAP EPS declined and Celero costs are explicitly called out, limiting upside conviction.

Market effects

Supports the payments and data services narrative that cash generation and mix shift can offset check-related declines, potentially influencing peer sentiment.

Limited, as the disclosure is company-specific with no stated regional macro shock.

Low, aside from generic macro/tariff sensitivity language that is not new.

Counterpoint

Investors may discount the guidance raise if Celero synergy capture is slower than management expects, especially given Q2 GAAP net income and EPS declines tied to acquisition costs.

Key entities

  • Deluxe Corporation

    Payments and data company reporting Q2 2026 results and raising full-year 2026 guidance to include Celero.

  • Celero acquisition

    Acquisition closed July 31, 2026, with one-time transaction costs noted in Q2 and post-closing forecast used for guidance.

Related articles

$DLXMed

Deluxe Q2 Earnings Call Highlights

Deluxe (NYSE:DLX) reported Q2 segment results, led by Data Solutions revenue up 21.4% to $82.3M and adjusted EBITDA of $18.1M. Merchant Services revenue rose 6.1% to $107.6M. Print revenue fell 4.3% to $235.9M. Deluxe closed its Celero acquisition on July 31 and raised 2026 guidance: revenue $2.095B-$2.12B, adj. EBITDA $455M-$475M, adj. EPS $3.60-$4.00, and FCF about $200M.

$DLXMed

DELUXE CORP (DLX): Completion of Acquisition or Disposition of Assets

DELUXE CORP (DLX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 tm2621737d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version REFINANCING FACILITY AGREEMENT NO. 2 REFINANCING FACILITY AGREEMENT NO. 2 dated as of July 31, 2026 (this “ Amendment ”), to the Credit Agreement, dated as of June 1, 2021 (as amended by the First Amendm

$DLXMed

Deluxe to Acquire Celero Commerce, Boosting Growth in Payments Sector

Deluxe Corporation will acquire Celero Commerce for $625 million, with the deal expected to close in Q3 2026, according to Deluxe. The company said the purchase will shift revenue toward its Payments and Data segments and expand merchant processing. Deluxe expects the combined unit to process about $70 billion in gross transaction volume by 2025 and target $15 million+ in cost synergies within two years.

$DLXHighAI 9/10

Deluxe to buy Celero Commerce for USD $625 million

Deluxe agreed to buy Celero Commerce for $625 million in cash, plus assumed seller transaction expenses and other adjustments, subject to regulatory approvals and customary closing conditions. Deluxe will fund via committed debt and its revolving credit facility. Deluxe expects the deal to add to adjusted EPS in year one, with $15+ million cost synergies within 24 months. Celero reported 2025 revenue of $200+ million and 28% adjusted EBITDA margin.

$DLXMedAI 8/10

Deluxe Acquires Celero Commerce for $625M to Vault into Top 10 Non - Bank Merchant Acquirers

Deluxe (NYSE: DLX) agreed to acquire Celero Commerce for $625 million in cash, announced June 18, 2026, with FT Partners as Celero’s exclusive advisor. Deluxe said the combined firms processed about $70 billion in gross transaction volume in 2025, including Celero’s $28+ billion pre-merger. The deal expands Deluxe’s payments and data reach and targets a top-10 position among non-bank merchant acquirers.

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.